Unnamed: 0,title,date,stock,sentiment
291168.0,Catalyst Pharmaceuticals Option Alert: Jun 19 $5 Calls Sweep (2) near the Ask: 861 @ $0.25 vs 3015 OI; Ref=$4.305,2020-05-13 13:25:00-04:00,CPRX,positive
291169.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,CPRX,negative
291170.0,"SunTrust Robinson Humphrey Maintains Buy on Catalyst Pharmaceuticals, Lowers Price Target to $10",2020-05-13 09:08:00-04:00,CPRX,negative
291171.0,Catalyst Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q1 sales results.,2020-05-11 16:38:00-04:00,CPRX,neutral
291172.0,"Catalyst Pharmaceuticals Q1 EPS $0.100 Beats $0.090 Estimate, Sales $29.100M Miss $31.460M Estimate",2020-05-11 16:24:00-04:00,CPRX,negative
291173.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,CPRX,neutral
291174.0,Shares of several healthcare companies are trading higher amid overall market strength. Several companies in the sector may also be benefiting from increased demand for therapies and medical supplies amid the coronavirus pandemic. UPDATE: Shares of some names in the sector moved higher later in the session following news that US Senator Sanders has suspended his presidential campaign.,2020-04-08 09:34:00-04:00,CPRX,positive
291175.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,CPRX,positive
291176.0,130 Biggest Movers From Yesterday,2020-03-18 06:06:00-04:00,CPRX,neutral
291177.0,10 Small-To-Mid-Cap Biotech Ideas For When The Coronavirus Fades,2020-03-17 17:13:00-04:00,CPRX,neutral
291178.0,94 Stocks Moving In Tuesday's Mid-Day Session,2020-03-17 12:41:00-04:00,CPRX,neutral
291179.0,34 Stocks Moving in Tuesday's Pre-Market Session,2020-03-17 07:46:00-04:00,CPRX,neutral
291180.0,Catalyst Pharmaceuticals Sees FY20 Firdapse Sales $135M-$155M,2020-03-16 17:28:00-04:00,CPRX,neutral
291181.0,"Catalyst Pharmaceuticals Q4 EPS $0.07 Misses $0.1 Estimate, Sales $30M Beat $29.4M Estimate",2020-03-16 17:28:00-04:00,CPRX,negative
291182.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,CPRX,neutral
291183.0,"Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Raises Price Target to $12",2020-02-14 07:03:00-05:00,CPRX,negative
291184.0,Shares of several healthcare and biotech companies are trading higher as unconfirmed reports of progress towards a coronavirus treatment raise investor sentiment amid the virus outbreak. NOTE: The WHO played down these reports and said there are no known treatments.,2020-02-05 09:47:00-05:00,CPRX,positive
291185.0,Catalyst Pharmaceuticals Option Alert: Jun 19 $2.5 Calls Sweep (24) near the Ask: 721 @ $2.101 vs 2259 OI; Ref=$4.19,2020-01-14 10:11:00-05:00,CPRX,positive
291186.0,50 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-01-08 08:31:00-05:00,CPRX,neutral
291187.0,50 Biggest Movers From Yesterday,2020-01-07 04:19:00-05:00,CPRX,neutral
291188.0,Catalyst Pharmaceuticals shares are trading higher after the company announced it sees 2019 Firdapse net product revenues of $102 million and 2020 net product revenues of $135 million.,2020-01-06 11:37:00-05:00,CPRX,positive
291189.0,Catalyst Pharma Sees 2019 Firdapse Net Product Revenues of $102M and 2020 Net Product Revenues of $135M,2020-01-06 08:23:00-05:00,CPRX,neutral
291190.0,5 Stocks Analysts Recommend Heading Into 2020,2020-01-01 12:07:00-05:00,CPRX,positive
291191.0,Catalyst Pharmaceuticals shares are trading higher. Not seeing any news to justify the price action.,2019-12-05 11:37:00-05:00,CPRX,positive
291192.0,Catalyst Pharmaceuticals Option Alert: Jun 19 $7.5 Calls Sweep (25) near the Ask: 664 @ $0.651 vs 45 OI; Ref=$4.75,2019-11-27 14:48:00-05:00,CPRX,positive
291193.0,﻿Catalyst Pharmaceuticals shares are trading lower on continued momentum after the company reported worse-than-expected Q3 sales results. The company also issued FY19 & FY20 sales guidance below analyst estimates.,2019-11-15 13:43:00-05:00,CPRX,neutral
291194.0,81 Biggest Movers From Yesterday,2019-11-14 05:20:00-05:00,CPRX,neutral
291195.0,54 Stocks Moving In Wednesday's Mid-Day Session,2019-11-13 12:08:00-05:00,CPRX,neutral
291196.0,Catalyst Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 sales results. The company also issued FY19 & FY20 sales guidance below analyst estimates.,2019-11-13 09:12:00-05:00,CPRX,neutral
291197.0,44 Stocks Moving in Wednesday's Pre-Market Session,2019-11-13 07:19:00-05:00,CPRX,neutral
291198.0,"The Daily Biotech Pulse: Merck Goes Shopping, Nuvectra Files For Bankruptcy Protection, Opiant Rips Higher",2019-11-13 07:10:00-05:00,CPRX,neutral
291199.0,Catalyst Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q3 sales results. The company also issued FY19 & FY20 sales guidance below analyst estimates.,2019-11-12 17:06:00-05:00,CPRX,neutral
291200.0,"Catalyst Pharmaceuticals Sees FY19 Sales ~$100M vs $111.01M Est., FY20 Sales $135M-$155M vs $166.63M Est.",2019-11-12 16:41:00-05:00,CPRX,neutral
291201.0,"Catalyst Pharmaceuticals Q3 EPS $0.13 Beats $0.11 Estimate, Sales $30.9M Miss $33.18M Estimate",2019-11-12 16:40:00-05:00,CPRX,negative
291202.0,"The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat",2019-11-12 07:20:00-05:00,CPRX,neutral
291203.0,Catalyst Pharmaceuticals shares are trading higher on seemingly no company-specific news.,2019-11-08 14:22:00-05:00,CPRX,neutral
291204.0,21 Stocks Moving In Monday's Pre-Market Session,2019-11-04 07:56:00-05:00,CPRX,neutral
291205.0,28 Biggest Movers From Yesterday,2019-10-31 07:47:00-04:00,CPRX,neutral
291206.0,28 Stocks Moving In Wednesday's Mid-Day Session,2019-10-30 12:10:00-04:00,CPRX,neutral
291207.0,Catalyst Pharmaceuticals shares are trading lower after the company announced that its Phase 3 trial of Firdapse in patients with congenital myasthenic syndromes did not meet its primary and secondary endpoints.,2019-10-30 08:42:00-04:00,CPRX,neutral
291208.0,13 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-10-30 07:32:00-04:00,CPRX,neutral
291209.0,22 Stocks Moving in Wednesday's Pre-Market Session,2019-10-30 07:15:00-04:00,CPRX,neutral
291210.0,"Catalyst Pharmaceuticals Phase 3 Trial of Firdapse in Patients With Congenital Myasthenic Syndromes Did Not Meet Its Primary, Secondary  Endpoints",2019-10-30 06:12:00-04:00,CPRX,neutral
291211.0,"Chmn McEnany Buys 10,000 Of Catalyst Pharmaceuticals @$4.89",2019-10-03 15:15:00-04:00,CPRX,neutral
291212.0,"Shares of several healthcare stocks are trading lower in sympathy with the overall market after the Institute for Supply Management said U.S. manufacturing activity shrunk to its lowest level since June 2009, adding fears of an economic slowdown.",2019-10-01 13:02:00-04:00,CPRX,negative
291213.0,24 Stocks Moving in Monday's Pre-Market Session,2019-09-30 08:41:00-04:00,CPRX,neutral
291214.0,Catalyst Pharmaceuticals Option Alert: Mar 20 $7.5 Calls at the Ask: 600 @ $0.75 vs 906 OI; Earnings 11/6 After Close [est] Ref=$5.22,2019-09-25 09:41:00-04:00,CPRX,positive
291215.0,14 Healthcare Stocks Moving In Tuesday's Pre-Market Session,2019-09-24 08:07:00-04:00,CPRX,neutral
291216.0,46 Biggest Movers From Yesterday,2019-09-24 04:02:00-04:00,CPRX,neutral
291217.0,"UPDATE: Catalyst Pharma Says Co. 'believes that if an acquisition or in-licensing opportunity were to be identified, the Company expects that it would also be able to raise the required funds...'",2019-09-23 14:58:00-04:00,CPRX,positive
291218.0,UPDATE: Catalyst Reiterates Similar Sentiment Shared When Stock Offering Was Cancelled On Sep. 13: 'does not believe raising additional capital in the public market through sales of equity in the foreseeable future would be in the best interest',2019-09-23 14:58:00-04:00,CPRX,positive
291219.0,Catalyst Pharma Issues Press Release Reporting It Is Not Aware Of Any Information About Co.'s Activities To Account For Price Action In Stock,2019-09-23 14:55:00-04:00,CPRX,neutral
291220.0,34 Stocks Moving In Monday's Mid-Day Session,2019-09-23 12:37:00-04:00,CPRX,neutral
291221.0,Catalyst Pharmaceuticals shares are trading lower. Not seeing any news to justify the price action.,2019-09-23 10:40:00-04:00,CPRX,neutral
291222.0,35 Stocks Moving In Friday's Mid-Day Session,2019-09-13 12:56:00-04:00,CPRX,neutral
291223.0,24 Healthcare Stocks Moving In Friday's Pre-Market Session,2019-09-13 08:44:00-04:00,CPRX,neutral
291224.0,24 Stocks Moving in Friday's Pre-Market Session,2019-09-13 07:54:00-04:00,CPRX,neutral
291225.0,Catalyst Pharma Shares Pop After Cancelling Public Offering,2019-09-13 07:49:00-04:00,CPRX,positive
291226.0,Catalyst Pharmaceuticals shares are trading higher after the company announced it will be canceling its previously announced public offering of common stock.,2019-09-13 07:41:00-04:00,CPRX,positive
291227.0,"The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans",2019-09-13 07:40:00-04:00,CPRX,neutral
291228.0,A Peek Into The Markets: US Stock Futures Surge Ahead Of Economic Reports,2019-09-13 07:13:00-04:00,CPRX,neutral
291229.0,58 Biggest Movers From Yesterday,2019-09-13 07:04:00-04:00,CPRX,neutral
291230.0,Catalyst Pharma Shares Up 10% Following News Offering Was Cancelled,2019-09-13 06:09:00-04:00,CPRX,positive
291231.0,"Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock",2019-09-13 06:03:00-04:00,CPRX,neutral
291232.0,50 Stocks Moving In Thursday's Mid-Day Session,2019-09-12 13:39:00-04:00,CPRX,neutral
291233.0,Stocks That Hit 52-Week Highs On Thursday,2019-09-12 10:51:00-04:00,CPRX,neutral
291234.0,Catalyst Pharmaceuticals shares are trading lower after the company reported an 8 million share common stock offering.,2019-09-12 09:32:00-04:00,CPRX,positive
291235.0,28 Healthcare Stocks Moving In Thursday's Pre-Market Session,2019-09-12 08:36:00-04:00,CPRX,neutral
291236.0,33 Stocks Moving in Thursday's Pre-Market Session,2019-09-12 07:59:00-04:00,CPRX,neutral
291237.0,"The Daily Biotech Pulse: Ardelyx Awaits Ruling On Constipation Drug, Double Dose Of Good News For Roche, Tocagen Flunks Brain Cancer Study",2019-09-12 07:38:00-04:00,CPRX,negative
291238.0,71 Biggest Movers From Yesterday,2019-09-12 05:33:00-04:00,CPRX,neutral
291239.0,"7 Stocks To Watch For September 12, 2019",2019-09-12 04:49:00-04:00,CPRX,neutral
291240.0,Catalyst Pharmaceuticals shares are trading lower after the company reported an 8 million share common stock offering.,2019-09-11 16:21:00-04:00,CPRX,positive
291241.0,Catalyst Pharmaceuticals Reports 8M Share Common Stock Offering,2019-09-11 16:19:00-04:00,CPRX,positive
291242.0,Catalyst Pharmaceuticals shares are trading higher on seemingly no company-specific news.,2019-09-11 15:04:00-04:00,CPRX,neutral
291243.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-09-11 12:27:00-04:00,CPRX,neutral
291244.0,25 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2019-09-11 08:21:00-04:00,CPRX,neutral
291245.0,26 Stocks Moving in Wednesday's Pre-Market Session,2019-09-11 07:59:00-04:00,CPRX,neutral
291246.0,"The Daily Biotech Pulse: Lexicon Snaps Sanofi Diabetes Partnership With $260M Settlement, Celyad Offering, Multiple Sclerosis Conference Gets Underway",2019-09-11 07:09:00-04:00,CPRX,neutral
291247.0,Stocks That Hit 52-Week Highs On Monday,2019-09-09 12:43:00-04:00,CPRX,neutral
291248.0,Stocks That Hit 52-Week Highs On Thursday,2019-08-29 10:15:00-04:00,CPRX,neutral
291249.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wed., August 21, 2019",2019-08-21 12:46:00-04:00,CPRX,positive
291250.0,Stocks That Hit 52-Week Highs On Wednesday,2019-08-21 10:17:00-04:00,CPRX,neutral
291251.0,"The Daily Biotech Pulse: Ra Pharma Earns Milestone, Aimmune Doses Patient In Egg Allergy Trial, Cara In-Licenses Platform",2019-08-21 07:40:00-04:00,CPRX,neutral
291252.0,Stocks That Hit 52-Week Highs On Tuesday,2019-08-20 10:27:00-04:00,CPRX,neutral
291253.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Fri., August 16, 2019",2019-08-16 12:59:00-04:00,CPRX,positive
291254.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Thu, August 15, 2019",2019-08-15 12:25:00-04:00,CPRX,positive
291255.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Screener Tool For Wed., August 14, 2019",2019-08-14 12:39:00-04:00,CPRX,positive
291256.0,"Top 10 Most Overbought Stocks Via Benzinga Pro's Radar Tool For Tue., August 13, 2019",2019-08-13 12:56:00-04:00,CPRX,positive
291257.0,﻿Shares of several healthcare companies are trading higher with the overall market after the U.S. announced it is excluding and delaying the additional 10% tariff on certain products.,2019-08-13 11:53:00-04:00,CPRX,positive
291258.0,"Catalyst Pharma Shares Tick Higher Above $5 Level; Hearing SunTrust Raised Price Target To New Street High At $11, Called Weakness A Buying Opportunity",2019-08-08 13:00:00-04:00,CPRX,positive
291259.0,25 Healthcare Stocks Moving In Today's Pre-Market Session,2019-08-08 08:35:00-04:00,CPRX,neutral
291260.0,42 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-07 21:24:00-04:00,CPRX,neutral
291261.0,Catalyst Pharmaceuticals shares are trading lower after the company reported Q2 results.,2019-08-07 16:30:00-04:00,CPRX,neutral
291262.0,"Catalyst Pharmaceuticals Q2 EPS $0.11 Beats $0.02 Estimate, Sales $28.8M Beat $18.49M Estimate",2019-08-07 16:25:00-04:00,CPRX,neutral
291263.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,CPRX,neutral
291264.0,Catalyst Pharmaceuticals shares are trading higher on seemingly no company-specific news.,2019-07-24 15:30:00-04:00,CPRX,neutral
291265.0,"Catalyst Pharmaceuticals CEO Buys 25,000 @ Avg Price: $3.23",2019-06-11 14:09:00-04:00,CPRX,neutral
291266.0,Catalyst Pharmaceuticals Announces Expansion of Firdapse Licensing Agreement To Include Japan,2019-05-30 08:06:00-04:00,CPRX,positive
291267.0,60 Biggest Movers From Yesterday,2019-05-16 05:12:00-04:00,CPRX,neutral
291268.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning of Tue., May 14, 2019",2019-05-14 10:35:00-04:00,CPRX,positive
291269.0,"Benzinga Pro's Top 8 Most-Searched Tickers For Morning of Mon., May 13, 2019",2019-05-13 10:24:00-04:00,CPRX,positive
291270.0,Catalyst Pharmaceuticals shares are trading higher after the company reported better-than-expected Q1 EPS and sales results upon the launch of its Firdapse.,2019-05-13 08:54:00-04:00,CPRX,positive
291271.0,30 Stocks Moving In Monday's Pre-Market Session,2019-05-13 08:15:00-04:00,CPRX,neutral
291272.0,"Catalyst Pharmaceutical Q1 EPS $(0.01) Beats $(0.13) Estimate, Sales $12.448M Beat $1.6M Estimate",2019-05-13 06:20:00-04:00,CPRX,neutral
291273.0,72 Biggest Movers From Friday,2019-05-13 05:09:00-04:00,CPRX,neutral
291274.0,"Earnings Scheduled For May 13, 2019",2019-05-13 04:06:00-04:00,CPRX,neutral
291275.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-05-11 08:40:00-04:00,CPRX,neutral
291276.0,71 Stocks Moving In Thursday's Mid-Day Session,2019-05-09 12:11:00-04:00,CPRX,neutral
291277.0,28 Stocks Moving In Thursday's Pre-Market Session,2019-05-09 08:08:00-04:00,CPRX,neutral
291278.0,95 Biggest Movers From Yesterday,2019-05-09 05:01:00-04:00,CPRX,neutral
291279.0,"Catalyst Pharmaceuticals shares are trading lower after the FDA approved competitor Jacobus Pharma's Lambert-Eaton myasthenic syndrome drug, Ruzurgi.",2019-05-08 15:40:00-04:00,CPRX,positive
291280.0,FBO Site Shows Catalyst Pharmaceuticals Awarded A 5 Year Blanket Purchase Agreement Contract From The US Government Department Of Veterans,2019-05-08 15:38:00-04:00,CPRX,positive
291281.0,75 Stocks Moving In Wednesday's Mid-Day Session,2019-05-08 12:24:00-04:00,CPRX,neutral
291282.0,72 Biggest Movers From Yesterday,2019-05-08 06:17:00-04:00,CPRX,neutral
291283.0,Mid-Afternoon Market Update: Dow Falls 600 Points; Solaredge Technologies Shares Surge Following Strong Q1 Results,2019-05-07 14:36:00-04:00,CPRX,positive
291284.0,Mid-Day Market Update: Nautilus Falls On Downbeat Q1 Results; Cohu Shares Surge,2019-05-07 12:35:00-04:00,CPRX,positive
291285.0,64 Stocks Moving In Tuesday's Mid-Day Session,2019-05-07 12:17:00-04:00,CPRX,neutral
291286.0,Catalyst Pharma Plummets On Competition For Pricey LEMS Drug,2019-05-07 11:10:00-04:00,CPRX,neutral
291287.0,Mid-Morning Market Update: Markets Open Lower; TransDigm Group Beats Q2 Estimates,2019-05-07 10:17:00-04:00,CPRX,negative
291288.0,Catalyst Pharmaceuticals shares are trading lower after the FDA approved the company's competitor to its Firdapse drug.,2019-05-07 09:33:00-04:00,CPRX,positive
291289.0,"The Daily Biotech Pulse: Osmotica Flies, Catalyst Plummets, GW Pharma On Track To File For Expanded Use Of Epidiolex",2019-05-07 08:20:00-04:00,CPRX,neutral
291290.0,31 Stocks Moving In Tuesday's Pre-Market Session,2019-05-07 08:05:00-04:00,CPRX,neutral
291291.0,25 Stocks Moving In Wednesday's Pre-Market Session,2019-05-01 08:30:00-04:00,CPRX,neutral
291292.0,"The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug",2019-04-26 08:02:00-04:00,CPRX,negative
291293.0,55 Biggest Movers From Yesterday,2019-04-26 04:49:00-04:00,CPRX,neutral
291294.0,"The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO",2019-03-28 07:54:00-04:00,CPRX,neutral
291295.0,42 Stocks Moving In Tuesday's Mid-Day Session,2019-03-26 13:20:00-04:00,CPRX,neutral
291296.0,28 Stocks Moving In Tuesday's Pre-Market Session,2019-03-26 08:39:00-04:00,CPRX,neutral
291297.0,Catalyst Pharmaceutical shares are trading lower after the stock rose 70% over the previous 5 trading sessions due to a presentation the company gave on its outlook at an Oppenheimer healthcare event.,2019-03-26 08:21:00-04:00,CPRX,neutral
291298.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Tues., Mar. 26, 2019",2019-03-26 08:19:00-04:00,CPRX,positive
291299.0,"The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs",2019-03-26 07:36:00-04:00,CPRX,positive
291300.0,52 Biggest Movers From Yesterday,2019-03-26 05:04:00-04:00,CPRX,neutral
291301.0,"Catalyst Pharmaceuticals shares are traded higher after the company gave a corporate overview at Oppenheimer's healthcare event. Catalyst highlighted 2 possible catalysts in presentation: Phase 3 data for CMS, MuSK-MG candidates.",2019-03-25 16:50:00-04:00,CPRX,positive
291302.0,41 Stocks Moving In Monday's Mid-Day Session,2019-03-25 12:51:00-04:00,CPRX,neutral
291303.0,"The Daily Biotech Pulse: Immutep Gets US Patent, Conatus NASH Disappointment, Eisai Moves On After Aducanumab Setback",2019-03-22 08:16:00-04:00,CPRX,negative
291304.0,52 Biggest Movers From Yesterday,2019-03-21 04:59:00-04:00,CPRX,neutral
291305.0,41 Stocks Moving In Wednesday's Mid-Day Session,2019-03-20 12:00:00-04:00,CPRX,neutral
291306.0,"Catalyst Pharmaceuticals shares are trading higher after Oppenheimer raised its price target on the company's stock from $9 to $10 per share, citing positive early launch metrics for the company's Firdapse drug.",2019-03-20 10:46:00-04:00,CPRX,positive
291307.0,Oppenheimer Earlier Reiterated Outperform Rating On Catalyst Pharmaceuticals And Raised Price Target From $9 To $10,2019-03-20 10:39:00-04:00,CPRX,neutral
291308.0,70 Biggest Movers From Yesterday,2019-03-20 05:36:00-04:00,CPRX,neutral
291309.0,45 Stocks Moving In Tuesday's Mid-Day Session,2019-03-19 13:21:00-04:00,CPRX,neutral
291310.0,45 Stocks Moving In Tuesday's Mid-Day Session,2019-03-19 13:10:00-04:00,CPRX,neutral
291311.0,"The Daily Biotech Pulse: FDA Nod For Roche And Amphastar, Milestone Payment Kicks In For Affimed",2019-03-19 07:40:00-04:00,CPRX,neutral
291312.0,Catalyst Pharmaceuticals shares are trading lower after the company reported worse-than-expected Q4 EPS.,2019-03-18 17:27:00-04:00,CPRX,neutral
291313.0,Catalyst Pharmaceutical Q4 EPS $(0.14) Misses $(0.12) Estimate,2019-03-18 16:20:00-04:00,CPRX,negative
291314.0,"Earnings Scheduled For March 18, 2019",2019-03-18 03:56:00-04:00,CPRX,neutral
291315.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings",2019-03-16 08:35:00-04:00,CPRX,neutral
291316.0,Catalyst Pharma Highlights Publication Of Phase 3 Trial Data For Firdapse For Treatment OF Lambert-Eaton Myasthenic Syndrome,2019-02-26 08:06:00-05:00,CPRX,neutral
291317.0,"Bernie Sanders Says ""If Catalyst Is Unwilling To Address The Concerns I Have Raised"", Will Ask FDA Commissioner Gottlieb To Act Immediately'",2019-02-21 13:47:00-05:00,CPRX,neutral
291318.0,Catalyst Pharmaceuticals Responds To Letter From Senator Bernie Sanders,2019-02-21 09:08:00-05:00,CPRX,neutral
291319.0,56 Biggest Movers From Yesterday,2019-02-05 04:26:00-05:00,CPRX,neutral
291320.0,35 Stocks Moving In Monday's Mid-Day Session,2019-02-04 12:22:00-05:00,CPRX,neutral
291321.0,"'Today, I am demanding that Catalyst explain why they raised the price of this drug by $375,000. No one in the United States of America should die because they cannot afford the medication they need.' -Bernie Sanders Tweets",2019-02-04 10:37:00-05:00,CPRX,negative
291322.0,22 Stocks Moving In Monday's Pre-Market Session,2019-02-04 07:59:00-05:00,CPRX,neutral
291323.0,Adam Feuerstein Tweet $CPRX Firdapse pricing scrutiny.   @megkesh wrote about the high cost of the drug in November. https://www.statnews.com/2018/12/13/catalyst-pharma-drug-price/ …,2019-02-04 06:57:00-05:00,CPRX,neutral
291324.0,"BZ NOTE: Catalyst Pharma Shares Up 3.7% Premarket On Light Volume As Co. Highlights Full Data For Previously-Disclosed Firdapse Analysis Now Available Online; Firdapse Was Approved By The FDA On Nov. 28, 2018",2019-01-04 08:15:00-05:00,CPRX,positive
291325.0,"UPDATE: Catalyst Pharma Notes Topline Results For Investigator-Sponsored Phase IIb Study Evaluating Firdapse Were Previously Disclosed; Says Full Results Of Safety, Efficacy Now Available Online; Co-Primary, Secondary Endpoints Were Met",2019-01-04 08:13:00-05:00,CPRX,positive
291326.0,Catalyst Pharma Highlights Publication of Clinical Data from the Investigator-Sponsored Phase IIb Study Evaluating Firdapse® for the Treatment of MuSK Antibody Positive Myasthenia Gravis,2019-01-04 08:11:00-05:00,CPRX,positive
291327.0,"The Daily Biotech Pulse: Proteostasis Delays Data, Akron Gets New CEO, Pfizer Halts Vaccine Trial",2018-12-21 07:58:00-05:00,CPRX,neutral
291328.0,"Catalyst Pharmaceuticals CEO: Mcenany Buys 20,000 @ Avg Price: $2.24",2018-12-19 16:27:00-05:00,CPRX,neutral
291329.0,Catalyst Pharmaceuticals Announces Definitive Agreement With Endo For Vigabatrin Tablets,2018-12-18 11:40:00-05:00,CPRX,positive
291330.0,Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved,2018-12-18 08:55:00-05:00,CPRX,positive
291331.0,"PiperJaffray Maintains Overweight on Catalyst Pharmaceuticals, Raises Price Target to $7.50",2018-12-13 12:03:00-05:00,CPRX,negative
291332.0,UPDATE: Catalyst Pharma Notes US Launch Of Firdapse Scheduled For Early In Q1'19,2018-12-03 08:06:00-05:00,CPRX,neutral
291333.0,"Catalyst Pharma Reports Will Host Conference Call, Webcast On Thurs., Dec. 13, 2018 At 8:30 a.m. EST To Discuss Commercialization Plan For Firdapse",2018-12-03 08:06:00-05:00,CPRX,neutral
291334.0,52 Biggest Movers From Friday,2018-12-03 05:42:00-05:00,CPRX,neutral
291335.0,38 Stocks Moving In Friday's Mid-Day Session,2018-11-30 12:33:00-05:00,CPRX,neutral
291336.0,48 Biggest Movers From Yesterday,2018-11-30 05:39:00-05:00,CPRX,neutral
291337.0,32 Stocks Moving In Thursday's Mid-Day Session,2018-11-29 12:42:00-05:00,CPRX,neutral
291338.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Thurs., Nov. 29, 2018",2018-11-29 11:02:00-05:00,CPRX,positive
291339.0,"Cantor Fitzgerald Reiterates Overweight on Catalyst Pharmaceuticals, Announces $8",2018-11-29 10:00:00-05:00,CPRX,negative
291340.0,"The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved",2018-11-29 08:09:00-05:00,CPRX,neutral
291341.0,"Catalyst Pharma Shares Resume Trade, Up 4%",2018-11-29 07:10:00-05:00,CPRX,positive
291342.0,Catalyst Pharma To Resume Trade At 7:10 a.m. EST,2018-11-29 07:05:00-05:00,CPRX,neutral
291343.0,Catalyst Pharmaceuticals Confirms FDA Approves Firdapse® (amifampridine) for the Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS),2018-11-29 06:04:00-05:00,CPRX,positive
291344.0,"FDA Approves Catalyst Pharmaceuticals' FIRDAPSE, The First Treatment For Lambert-Eaton Myasthenic Syndrome",2018-11-28 18:18:00-05:00,CPRX,positive
291345.0,"Catalyst Pharmaceuticals Shares Halted, News Pending",2018-11-28 18:04:00-05:00,CPRX,positive
291346.0,"The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings",2018-11-28 07:46:00-05:00,CPRX,neutral
291347.0,Catalyst Pharma Shares Resume,2018-11-27 16:45:00-05:00,CPRX,positive
291348.0,Catalyst Pharma Shares To Resume Trade At 5 p.m. EST,2018-11-27 16:40:00-05:00,CPRX,positive
291349.0,"Catalyst Pharmaceuticals, Inc. Shares To Resume Trade At 4:45 p.m. EDT",2018-11-27 16:29:00-05:00,CPRX,positive
291350.0,UPDATE: Catalyst Pharma Reports A Contractor Working On A Web Page Unintentionally Allowed A Live Screen To Be Seen Which Reflected Possible Approval Had Already Been Received,2018-11-27 16:14:00-05:00,CPRX,positive
291351.0,Catalyst Pharma Reports No Decision Has Yet Been Received From FDA Related To Co.'s New Drug Application For Firdapse,2018-11-27 16:13:00-05:00,CPRX,negative
291352.0,Catalyst Pharma Shares Halted Down 0.7% For Session; Stock Had Spiked As Much As 11% Earlier Following Trader Circulation Of Website Showing Approval For Co.'s Firdapse; Website Was Apparently Later Taken Down,2018-11-27 15:22:00-05:00,CPRX,positive
291353.0,Catalyst Pharma Shares Halted News Pending,2018-11-27 15:16:00-05:00,CPRX,positive
291354.0,Catalyst Pharma Shares Spike ~4-5% As Traders Circulate Unconfirmed Word Of Approval For Co. Drug Candidate,2018-11-27 14:20:00-05:00,CPRX,positive
291355.0,"The Week Ahead In Biotech: ASH 2018, PDUFA Dates, Clinical Trials And Earnings",2018-11-25 09:41:00-05:00,CPRX,neutral
291356.0,'Catalyst Pharma: A Rare Orphan Drug Opportunity With Low Risk' -Seeking Alpha,2018-11-23 09:40:00-05:00,CPRX,negative
291357.0,"Catalyst Pharmaceutical Partners, Inc. Q3 EPS $(0.08), Inline",2018-11-07 17:46:00-05:00,CPRX,neutral
291358.0,Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates,2018-11-01 09:26:00-04:00,CPRX,neutral
291359.0,Cantor Fitzgerald's 7 Buys For 7 Biotechs,2018-09-21 15:32:00-04:00,CPRX,neutral
291360.0,"Cantor Fitzgerald Initiates Coverage On Catalyst Pharmaceuticals with Overweight Rating, Announces $8 Price Target",2018-09-21 08:43:00-04:00,CPRX,negative
291361.0,30 Stocks Moving In Wednesday's Pre-Market Session,2018-09-12 08:17:00-04:00,CPRX,neutral
291362.0,44 Biggest Movers From Friday,2018-09-04 05:33:00-04:00,CPRX,neutral
291363.0,33 Stocks Moving In Friday's Mid-Day Session,2018-08-31 12:34:00-04:00,CPRX,neutral
291364.0,Catalyst Pharmaceuticals Q2 EPS $(0.06) Beats $(0.08) Estimate,2018-08-07 16:51:00-04:00,CPRX,neutral
291365.0,"Oppenheimer Initiates Coverage On Catalyst Pharmaceuticals with Outperform Rating, Announces $6 Price Target",2018-07-13 09:17:00-04:00,CPRX,neutral
291366.0,"Catalyst Pharma Shares Up 3.8% After Hours; Oppenheimer Initiates Coverage With Outperform Rating, $6 Price Target",2018-07-12 16:27:00-04:00,CPRX,positive
291367.0,"Catalyst Pharmaceuticals Director O'Keeffe  Buys 4,000 @ Avg Price: $3.31",2018-06-07 15:38:00-04:00,CPRX,neutral
291368.0,41 Biggest Movers From Yesterday,2018-05-31 04:45:00-04:00,CPRX,neutral
291369.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-05-30 12:26:00-04:00,CPRX,neutral
291370.0,Catalyst Pharmaceuticals Shares Up 10.3% After Co. Earlier Announced FDA Acceptance Of NDA And Priority Review Status For Firdapse LEMS Treatment,2018-05-29 14:57:00-04:00,CPRX,positive
291371.0,"Catalyst Pharmaceuticals Announces FDA Acceptance of NDA and Priority Review Status for Firdapse, PDUFA Date Set for November 28, 2018",2018-05-29 08:06:00-04:00,CPRX,positive
291372.0,48 Biggest Movers From Yesterday,2018-05-15 04:26:00-04:00,CPRX,neutral
291373.0,"Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results",2018-05-10 09:44:00-04:00,CPRX,neutral
291374.0,"The Week Ahead In Biotech: PDUFA Dates, Earnings, IPOs And More",2018-05-06 18:19:00-04:00,CPRX,neutral
291375.0,Catalyst Pharma Reports Enrollment Of First Patient In Phase 3 Trial Of Firdapse In MusK Antibody Positive Myasthenia Gravis,2018-04-19 08:13:00-04:00,CPRX,positive
291376.0,36 Biggest Movers From Yesterday,2018-04-05 04:40:00-04:00,CPRX,neutral
291377.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-04-04 12:50:00-04:00,CPRX,neutral
291378.0,Catalyst Pharma Reports Submission Of NDA For Firdapse For Treatment Of Lambert-Eaton Myasthenic Syndrome,2018-03-29 08:20:00-04:00,CPRX,neutral
291379.0,Catalyst Pharmaceuticals Reports Q4 EPS $(0.06) vs $(0.06) Est.,2018-03-14 16:14:00-04:00,CPRX,neutral
291380.0,"The Week Ahead In Biotech: Earnings, PDUFA Dates And More",2018-03-11 16:58:00-04:00,CPRX,neutral
291381.0,Catalyst Pharmaceuticals Gets Positive FDA Advise On Firdapse NDA Refiling,2018-02-15 11:18:00-05:00,CPRX,positive
291382.0,Catalyst Pharmaceuticals Announces Plans to Resubmit New Drug Application for Firdapse,2018-02-12 08:06:00-05:00,CPRX,neutral
291383.0,40 Biggest Movers From Yesterday,2017-11-29 05:02:00-05:00,CPRX,neutral
291384.0,35 Stocks Moving In Tuesday's Mid-Day Session,2017-11-28 12:23:00-05:00,CPRX,neutral
291385.0,Catalyst Pharma Prices Offering Of ~14.29M Shares At $3.50/Share,2017-11-28 09:18:00-05:00,CPRX,positive
291386.0,30 Stocks Moving In Tuesday's Pre-Market Session,2017-11-28 08:08:00-05:00,CPRX,neutral
291387.0,45 Biggest Movers From Yesterday,2017-11-28 05:21:00-05:00,CPRX,neutral
291388.0,"10 Stocks To Watch For November 28, 2017",2017-11-28 04:56:00-05:00,CPRX,neutral
291389.0,10 Stocks Moving In Monday's After-Hours Session,2017-11-27 17:19:00-05:00,CPRX,neutral
291390.0,Catalyst Pharma Shares Down 5% Following News Of 11M Share Common Stock Offering,2017-11-27 16:25:00-05:00,CPRX,positive
291391.0,Catalyst Pharmaceuticals Announces 11M Share Common Stock Offering,2017-11-27 16:03:00-05:00,CPRX,positive
291392.0,34 Stocks Moving In Monday's Mid-Day Session,2017-11-27 12:25:00-05:00,CPRX,neutral
291393.0,32 Stocks Moving In Monday's Pre-Market Session,2017-11-27 08:03:00-05:00,CPRX,neutral
291394.0,"Catalyst Pharmaceuticals Announces 'Positive' Top-Line Results from Second Phase 3 Clinical Trial of Firdapse in Patients with Lambert-Eaton Myasthenic Syndrome, Company Plans to Submit NDA in Q1 2018",2017-11-27 06:31:00-05:00,CPRX,neutral
291395.0,Catalyst Pharma Reports Phase 2 Study For Firdapse In Ambulatory Patients With SMA,2017-11-21 08:04:00-05:00,CPRX,neutral
291396.0,Catalyst Pharma Reports Q3 Adj. EPS $(0.05) vs $(0.06) Est.,2017-11-08 16:42:00-05:00,CPRX,neutral
291397.0,UPDATE: Catalyst Pharma Says Expected NDA Submission For Firdapse Moves From End Of '17 To Q1'18,2017-08-30 08:05:00-04:00,CPRX,neutral
291398.0,"UPDATE: Catalyst Pharma Says FDA Granted SPA Deal For Phase 3 MuSK-MG Trial, Enrollment For Second Phase 3 Trial For LEMS Nearing Completion",2017-08-30 08:04:00-04:00,CPRX,positive
291399.0,Catalyst Pharma Offers Update On Status Of Firdapse Development Activities,2017-08-30 08:04:00-04:00,CPRX,neutral
291400.0,Catalyst Pharmaceuticals Reports Q2 Adj. EPS $(0.05) vs $(0.06) Est.,2017-08-09 16:34:00-04:00,CPRX,neutral
291401.0,10 Biggest Mid-Day Losers For Thursday,2017-07-13 12:39:00-04:00,CPRX,negative
291402.0,Mid-Morning Market Update: Markets Edge Higher; Delta Air Lines Profit Misses Expectations,2017-07-13 10:15:00-04:00,CPRX,positive
291403.0,22 Stocks Moving In Thursday's Pre-Market Session,2017-07-13 08:04:00-04:00,CPRX,neutral
291404.0,S-3 From Catalyst Pharma Shows $150M Mixed Securities Shelf Offering,2017-07-12 16:54:00-04:00,CPRX,positive
291406.0,Mid-Morning Market Update: Markets Open Lower; Lennar Tops Q2 Expectations,2017-06-20 10:12:00-04:00,CPRX,positive
291407.0,"Catalyst Pharma Reports Q1 Adj. EPS $(0.06), Inline",2017-05-10 16:36:00-04:00,CPRX,neutral
291408.0,18 Biggest Mid-Day Losers For Thursday,2017-03-16 13:10:00-04:00,CPRX,negative
291409.0,Catalyst Pharmaceuticals Reports Q4 EPS $(0.05) vs. (0.07) Est.,2017-03-15 16:34:00-04:00,CPRX,neutral
291410.0,Mid-Afternoon Market Update: Crude Oil Up Over 2%; FTD Companies Shares Plunge,2017-03-15 14:42:00-04:00,CPRX,negative
291411.0,18 Biggest Mid-Day Gainers For Wednesday,2017-03-15 12:38:00-04:00,CPRX,neutral
291412.0,Mid-Day Market Update: FTD Companies Drops After Q4 Results; Cesca Therapeutics Shares Surge,2017-03-15 12:13:00-04:00,CPRX,positive
291413.0,"Catalyst Pharmaceuticals Reports Data from Investigator-Sponsored Trial of Firdapse, Co. Says It Intends To Proceed To U.S. Multi-Center Pivotal Trial",2017-03-15 08:06:00-04:00,CPRX,neutral
291414.0,"Biocept, Catalyst Pharma Report Collaboration for Providing Liquid Biopsy Test for Small Cell Lung Cancer to Patients with LEMS, No Terms Disclosed",2017-03-14 08:06:00-04:00,CPRX,negative
291415.0,Benzinga's Option Alert Recap From February 24,2017-02-24 16:40:00-05:00,CPRX,positive
291416.0,Option Alert: Catalyst Pharma Mar 2.5 Calls Sweep: 900 @  ASK  $0.10: 900 traded vs 396 OI:,2017-02-24 12:25:00-05:00,CPRX,positive
291417.0,Catalyst Pharmaceuticals Announces First Patient Enrolled in Second Phase 3 Trial of Firdapse in Lambert-Eaton myasthenic syndrome,2016-12-15 08:03:00-05:00,CPRX,neutral
291418.0,"Catalyst Pharmaceuticals Provides Update on its Clinical Trial for Patients with Congenital Myasthenic Syndromes, To Now Allow Adult Patients Participate With Number of Patients Increased By ~20 People",2016-12-08 08:05:00-05:00,CPRX,positive
291419.0,Catalyst Pharma Reports Q3 Adj. EPS $(0.05) vs $(0.06) Est.,2016-11-09 16:23:00-05:00,CPRX,neutral
291420.0,Catalyst Pharma Reports Received SPA from FDA for Second Phase 3 Trial Evaluating Firdapse for Treatment of LEMS,2016-10-31 08:04:00-04:00,CPRX,neutral
291421.0,Mid-Afternoon Market Update: Dow Gains 125 Points; Net 1 Shares Spike Higher,2016-10-05 14:41:00-04:00,CPRX,positive
291422.0,18 Biggest Mid-Day Gainers For Wednesday,2016-10-05 12:40:00-04:00,CPRX,neutral
291423.0,Mid-Day Market Update: Crude Oil Up Over 2%; AZZ Shares Drop Following Q2 Results,2016-10-05 12:21:00-04:00,CPRX,negative
291424.0,Mid-Morning Market Update: Markets Open Higher; Constellation Brands Tops Q2 Views,2016-10-05 10:19:00-04:00,CPRX,positive
291425.0,8 Biggest Price Target Changes For Wednesday,2016-10-05 10:17:00-04:00,CPRX,neutral
291426.0,Benzinga's Top Upgrades,2016-10-05 09:20:00-04:00,CPRX,positive
291427.0,"PiperJaffray Upgrades Catalyst Pharmaceuticals to Overweight, Raises PT to $4.00",2016-10-05 06:06:00-04:00,CPRX,negative
291428.0,25 Stocks Which Rallied Three Days On Increasing Volume,2016-09-26 09:18:00-04:00,CPRX,neutral
291429.0,20 Stocks Which Rallied Three Days On Increasing Volume,2016-09-23 09:19:00-04:00,CPRX,neutral
291430.0,Catalyst Pharma Reports Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports,2016-09-19 08:04:00-04:00,CPRX,neutral
291431.0,Catalyst Pharmaceuticals Reports FDA Orphan Drug Designation of Firdapse For Treatment of Myasthenia Gravis,2016-09-02 10:41:00-04:00,CPRX,neutral
291432.0,Catalyst Pharma Reports Q2 Adj. EPS $(0.06) vs $(0.08) Est.,2016-08-09 16:21:00-04:00,CPRX,neutral
291433.0,8 Biggest Mid-Day Gainers For Monday,2016-06-13 12:31:00-04:00,CPRX,neutral
291434.0,10 Stocks Moving In Monday's Pre-Market Session,2016-06-13 08:25:00-04:00,CPRX,neutral
291435.0,Catalyst Pharmaceuticals Announces Agreement with FDA on Confirmatory Phase 3 Study Protocol for Firdapse in Lambert-Eaton Myasthenic Syndrome,2016-06-13 08:03:00-04:00,CPRX,positive
291436.0,Catalyst Pharmaceuticals Reduces Workforce By 30%,2016-05-17 08:04:00-04:00,CPRX,neutral
291437.0,UPDATE: Catalysts Says 'we continue to believe that our currently available resources will be sufficient to complete the development of Firdapse and refile an NDA for Firdapse.',2016-05-10 16:57:00-04:00,CPRX,neutral
291438.0,"Catalyst Pharma Reports Q1 Adj. EPS $(0.07), Inline",2016-05-10 16:56:00-04:00,CPRX,neutral
291439.0,"Director O'Keeffe Buys 20,000 Shares of Catalyst Pharmaceuticals @$0.60/Share -Form 4",2016-04-27 08:22:00-04:00,CPRX,positive
291440.0,"Chmn McEnany Buys 50,000 Shares of Catalyst Pharmaceuticals @$0.65/Share -Form 4",2016-04-26 14:08:00-04:00,CPRX,positive
291441.0,Stocks Hitting 52-Week Lows,2016-04-26 10:11:00-04:00,CPRX,negative
291442.0,Piper Jaffray Downgrades Catalyst Pharmaceuticals to Neutral,2016-04-26 08:33:00-04:00,CPRX,neutral
291443.0,UPDATE: Catalyst Pharmaceuticals Says FDA Requested Submission of Positive Results from Additional Adequate and Well-controlled Study in Patients with LEMS,2016-04-26 06:59:00-04:00,CPRX,positive
291444.0,"Catalyst Pharmaceuticals Says FDA Wants Additional Positive Results From An Adequate, Well-Controlled Study In Patient With LENS Outside Of Phase 3 LMS-002 Trial",2016-04-26 06:57:00-04:00,CPRX,positive
291445.0,Catalyst Pharmaceuticals Provides Regulatory Update on Firdapse,2016-04-26 06:57:00-04:00,CPRX,neutral
291446.0,"Catalyst Pharma Reports Q4 EPS $(0.07), Inline",2016-03-15 16:35:00-04:00,CPRX,neutral
291447.0,Mid-Afternoon Market Update: Dow Gains Over 250 Points; Catalyst Pharmaceuticals Shares Slide,2016-02-17 14:34:00-05:00,CPRX,positive
291448.0,Mid-Day Market Update: Crude Oil Surges 5%; Fossil Group Shares Rise On Strong Results,2016-02-17 12:02:00-05:00,CPRX,positive
291449.0,Catalyst Pharmaceuticals Crashes 50% Following 'Refusal To File' Letter From FDA,2016-02-17 10:16:00-05:00,CPRX,neutral
291450.0,Hearing Catalyst Pharma Defended at SunTrust,2016-02-17 10:05:00-05:00,CPRX,neutral
291451.0,"Catalyst Pharmaceuticals Receives ""Refusal to File"" Letter From the FDA on Its NDA for Firdapse",2016-02-17 06:52:00-05:00,CPRX,neutral
291452.0,Catalyst Pharma Reports Beginning Of Firdapse In Patients With MuSK-Antibody Positive Myasthenia Gravis,2016-02-08 08:05:00-05:00,CPRX,positive
291453.0,"Chairman McEnany Buys 25,000 Shares of Catalyst Pharmaceuticals @$2.39/Share -Form 4",2015-12-28 13:29:00-05:00,CPRX,positive
291454.0,Catalyst Pharmaceuticals Gives NDA Submission to FDA for Firdapse for the Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes,2015-12-17 08:03:00-05:00,CPRX,neutral
291455.0,"Catalyst Pharma Offers Top-Line Results in Phase 1(b) Trial of CPP-115: Showed Significant Increases in Brain Levels of Surrogate Marker for Potential Efficacy, GABA",2015-12-16 08:38:00-05:00,CPRX,positive
291456.0,Catalyst Pharma Reports Q3 Adj. EPS $(0.06) vs $(0.07) Est.,2015-11-09 16:37:00-05:00,CPRX,neutral
291457.0,Catalyst Pharmaceuticals Reports Notice of Allowance of a U.S. Patent Application for the Method of Treating Tourette's Disorder With GABA-Aminotransferase Inactivators,2015-10-13 08:03:00-04:00,CPRX,negative
291458.0,Catalyst Pharmaceuticals Announces a Clinical Trial for Pediatric Patients With Congenital Myasthenic Syndromes,2015-10-06 08:06:00-04:00,CPRX,neutral
291459.0,"Catalyst Pharmaceuticals Chairman Mcenany Buys 10,000 Shares @$2.81/Share -Form 4",2015-10-01 15:45:00-04:00,CPRX,positive
291460.0,Catalyst Pharma Names Paul Merrigan as Chief Commercial Officer,2015-08-17 08:03:00-04:00,CPRX,neutral
291461.0,Catalyst Pharma Reports Q2 Adj. Loss of $0.06/Share vs Loss of $0.08/Share Est.,2015-08-10 16:31:00-04:00,CPRX,negative
291462.0,Catalyst Pharma Reports Initiation of Rolinng NDA Submission for Firdapse for Treatment of LEMS,2015-07-22 13:25:00-04:00,CPRX,neutral
291463.0,Catalyst Pharmaceuticals Names Dr. Gary Ingenito Chief Medical Officer,2015-06-30 08:03:00-04:00,CPRX,neutral
291464.0,Mid-Afternoon Market Update: Dow Drops Over 150 Points; Nektar Therapeutics Shares Spike Higher,2015-06-24 14:58:00-04:00,CPRX,positive
291465.0,Mid-Day Market Update: Box Surges Following Announcement Of Partnership With IBM On Cloud; Sunedison Semiconductor Shares Fall,2015-06-24 14:34:00-04:00,CPRX,positive
291466.0,Mid-Morning Market Update: Markets Open Lower; Lennar Beats Q2 Estimates,2015-06-24 10:20:00-04:00,CPRX,negative
291467.0,Morning Market Gainers,2015-06-24 09:42:00-04:00,CPRX,neutral
291468.0,"MLV & Co. Initiates Coverage on Catalyst Pharmaceuticals at Buy, Announces $14.00 PT",2015-06-24 09:24:00-04:00,CPRX,neutral
291469.0,Catalyst Pharmaceuticals Reports Encouraging Top-Line Results in Proof-of-Concept Trial of Vigabatrin in Patients With Treatment-Refractory Tourette's Disorder,2015-06-24 08:03:00-04:00,CPRX,positive
291470.0,SunTrust's 5 Biotech Picks For The Next 6 Months,2015-06-17 13:24:00-04:00,CPRX,neutral
291471.0,Catalyst Pharma Names Richard Daly as Interim CCO,2015-05-28 11:20:00-04:00,CPRX,neutral
291472.0,"Catalyst Pharmaceutica Director Denkhaus Buys 15,000 Shares @$3.71/Share -Form 4",2015-04-28 08:51:00-04:00,CPRX,positive
291473.0,"Catalyst Shares Resume Trading, Down ~30% Now",2015-04-24 12:58:00-04:00,CPRX,positive
291474.0,"UPDATE: Catalyst Halts Limit Up-Limit Down, No News.  Shares Have Lost ~36%",2015-04-24 12:54:00-04:00,CPRX,negative
291475.0,Catalyst Halted Again,2015-04-24 12:53:00-04:00,CPRX,neutral
291476.0,Catalyst Shares Resume Trading,2015-04-24 12:52:00-04:00,CPRX,positive
291477.0,Catalyst Shares Halt After Rapid Decline,2015-04-24 12:49:00-04:00,CPRX,positive
291478.0,Adam Feuerstein Tweet: $CPRX Competitor Surprises With Positive Orphan Disease Drug Study Results thestreet.com/story/13125612… Jacobus Pharma is still in LEMS hunt.,2015-04-24 12:09:00-04:00,CPRX,positive
291479.0,Catalyst Pharmaceuticals Announces Oral Presentation of Firdapse Phase 3 Trial Data at American Academy of Neurology Annual Meeting (AAN),2015-04-14 08:15:00-04:00,CPRX,neutral
291480.0,Catalyst Pharmaceuticals Reports Presentation of Firdapse Phase 3 Trial Data at American Academy of Neurology Annual Meeting,2015-04-14 08:07:00-04:00,CPRX,neutral
291481.0,Stocks Hitting 52-Week Highs,2015-03-17 10:12:00-04:00,CPRX,neutral
291482.0,"Catalyst Pharma Reports Q4 Adj. Loss of $0.06/Share, Inline",2015-03-16 08:04:00-04:00,CPRX,negative
291483.0,Are There Any Small-Cap Gems In Health Care?,2015-03-05 23:02:00-05:00,CPRX,positive
291484.0,Catalyst Pharmaceuticals Announces FDA Orphan Drug Designation of Firdapse for Treatment of Congenital Myasthenic Syndromes,2015-03-05 10:39:00-05:00,CPRX,neutral
291486.0,"Catalyst Pharmaceuticals Appoints Richard Daly, Donald Denkhaus To BOD",2015-02-19 12:05:00-05:00,CPRX,neutral
291487.0,Why Piper Jaffray's Charles Duncan Still Likes Catalyst Pharmaceuticals,2015-02-18 10:15:00-05:00,CPRX,positive
291488.0,Catalyst Pharmaceutical Partners Prices 10M Share Offering @$3.25/Share,2015-02-04 09:01:00-05:00,CPRX,positive
291489.0,Catalyst Pharmaceutical Partners Announces Commencement of Public Offering of Common Stock,2015-02-03 16:48:00-05:00,CPRX,neutral
291490.0,"Catalyst Pharma Offers '15 Goals: Expecting Pre-NDA Meeting with FDA, NDA Submission of Firdapse, to Develop Regulatory Strategy for Firdapse",2015-01-12 08:05:00-05:00,CPRX,neutral
291491.0,"Catalyst Pharma REports Naming of David Muth as Exec VP, Chief Commercial Officer",2015-01-05 08:04:00-05:00,CPRX,neutral
291492.0,"Catalyst Pharmaceuticals Appoints David D. Muth, Executive VP, Chief Commercial Officer",2015-01-05 08:03:00-05:00,CPRX,neutral
291493.0,"Catalyst Pharmaceuticals Announces the Passing of Hubert E. Huckel, Co-Founder and Director",2014-12-16 15:45:00-05:00,CPRX,neutral
291494.0,"Catalyst Pharma Reports Notice of Allowance of US Patent Application for Reduction, Elimination of Visual Field Defects by Treating Patients with CPP-115",2014-11-24 08:04:00-05:00,CPRX,negative
291495.0,"Catalyst Pharmaceutical Partners, Inc. Reports Q3 EPS of $(0.06) vs $(0.05) Est",2014-11-14 08:04:00-05:00,CPRX,neutral
291496.0,"From 10-Q Filing: Catalyst Pharmaceutical Partners, Inc. Reports Q3 EPS of $(0.07) vs $(0.05) Est",2014-11-13 16:47:00-05:00,CPRX,neutral
291497.0,Catalyst Pharmaceuticals Announces Proposed Settlement Of Pending Securities Class Action Lawsuit,2014-11-04 08:08:00-05:00,CPRX,positive
291498.0,Catalyst Pharmaceuticals To Present Firdapse Phase 3 Trial Results At The 61st Annual Meeting Of The American Association Of Neuromuscular And Electrodiagnostic Medicine,2014-10-27 08:11:00-04:00,CPRX,neutral
291499.0,"Midday Gainers From October 8 - GT Advanced Technologies Inc, Unilife Corp And More",2014-10-08 13:11:00-04:00,CPRX,positive
291500.0,Catalyst Pharmaceuticals to Present Top-Line Safety And Efficacy Results From Phase 3 Firdapse Trial At 139th Annual Meeting Of The American Neurological Association,2014-10-08 08:04:00-04:00,CPRX,positive
291501.0,Morning Market Movers ,2014-09-30 09:37:00-04:00,CPRX,neutral
291502.0,"Shares of Catalyst Pharma Resume Trade, Now Up ~20%",2014-09-29 16:38:00-04:00,CPRX,positive
291503.0,Shares of Catalyst Pharma to Resume Trade at 4:35 p.m. EDT,2014-09-29 16:08:00-04:00,CPRX,positive
291504.0,UPDATE: Catalyst Expects to Begin Rolling NDA Submission in Early 2015,2014-09-29 16:04:00-04:00,CPRX,neutral
291505.0,UPDATE: Catalyst Pharma Reports Phase 3 Study Data for Firdapse Shows Met Primary Endpoints,2014-09-29 16:04:00-04:00,CPRX,neutral
291506.0,Catalyst Pharma Reports Phase 3 Study Data for Firdapse Shows Met Primary Endpoints,2014-09-29 16:03:00-04:00,CPRX,neutral
291507.0,Catalyst Pharma Shares Halted News Pending,2014-09-29 16:00:00-04:00,CPRX,positive
291508.0,Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115,2014-09-02 08:04:00-04:00,CPRX,positive
291509.0,"Catalyst Pharmaceutical Partners, Inc. Reports Q2 EPS of $(0.05) vs $(0.07) Est",2014-08-14 08:05:00-04:00,CPRX,neutral
291510.0,Catalyst Pharmaceutical Partners Provides Updates On Progress of Phase 3 Firdapse Study In Patients With Lambert-Eaton Myasthenic Syndrome (LEMS),2014-08-11 08:05:00-04:00,CPRX,positive
291511.0,"Catalyst Pharmaceutical Partners COO Miller Buys 100,000 Shares @$2.17/Share -Form 4",2014-06-04 18:42:00-04:00,CPRX,positive
291512.0,"Catalyst Pharmaceutical Partners Chairman Mcenany Buys 25,000 Shares @$1.89/Share -Form 4",2014-05-21 16:17:00-04:00,CPRX,positive
291513.0,"Catalyst Pharmaceutical Partners, Inc. Reports Q1 EPS of $(0.07) vs $(0.06) Est; Revenue of $0.00",2014-05-16 08:04:00-04:00,CPRX,neutral
291514.0,"Piper Jaffray Initiates Coverage on Catalyst Pharmaceutical Partners, Inc. at Overweight, Announces $4.00 PT",2014-04-14 08:50:00-04:00,CPRX,negative
291515.0,"Catalyst Pharmaceutical Announces Closing Public Offering, $26.8M Proceeds Expected",2014-04-08 10:31:00-04:00,CPRX,neutral
291516.0,Morning Market Movers ,2014-04-03 09:42:00-04:00,CPRX,neutral
291517.0,Catalyst Pharma Prices 11.3M Shares at $2.21/Share,2014-04-03 09:02:00-04:00,CPRX,positive
291518.0,Adam Feuerstein tweets: '$CPRX raises money right in front of ph3 firdapse results. Awesome!',2014-04-02 16:09:00-04:00,CPRX,neutral
291519.0,Catalyst Pharam Announces Commencement of Public Offering of Common Stock,2014-04-02 16:05:00-04:00,CPRX,neutral
291520.0,Catalyst Pharma Closes Enrollment in Pivotal Phase 3 Trial of Firdapse in Patients with Lambert-Eaton Myastenic Syndrome,2014-04-01 08:04:00-04:00,CPRX,neutral
291521.0,Catalyst Pharm Names Barrett McGrath as Chief Commercial Officer,2014-03-28 08:03:00-04:00,CPRX,neutral
291522.0,Catalyst Pharma Announces Recommendation of DMC to Continue Pivotal Phase 3 Clinical Trial for Firdapse,2014-03-25 08:05:00-04:00,CPRX,neutral
291523.0,"Catalyst Pharmaceutical Partners, Inc. Reports Q4 EPS of $(0.05) vs $(0.07) Est",2014-03-19 08:03:00-04:00,CPRX,neutral
291524.0,"Sizmek, Catalyst Pharmaceutical Partners, Lionbridge Technologies, Celldex Therapeutics, MacroGenics, Dot Hill Systems, Torchlight Energy Resources, ICalavo Growers Presenting at Roth Conference at 1:03 PM ET",2014-03-10 13:32:00-04:00,CPRX,positive
291525.0,Catalyst Pharma Says Study of Cardiac Safety in Phase 3 Trial of Firdapse Met Primary Endpoint,2014-01-08 08:04:00-05:00,CPRX,positive
291526.0,Catalyst Pharma Says Suit Dismissed Without Prejudice,2014-01-07 08:04:00-05:00,CPRX,positive
291527.0,"Catalyst Pharma Reports Successful Completion of Type B FDA Meeting, Will Submit Data from Added In-Vitro Preclinical Trial",2014-01-06 08:05:00-05:00,CPRX,positive
291528.0,Morning Market Movers ,2013-11-18 09:57:00-05:00,CPRX,neutral
291529.0,"Catalyst Pharma Says CPP-115 Was Well Tolerated in Preclinical Model, Showed Efficacy at Lower Doses",2013-11-18 08:04:00-05:00,CPRX,neutral
291530.0,"Catalyst Pharma Says Expecting Top-Line Results in Double Blind Part of Study, Should Be Released Q2 2014",2013-10-29 08:04:00-04:00,CPRX,negative
291531.0,"Catalyst Pharma Says Expecting to Issue Phase III Data During Q2 2014, Says Committee Recommends Continuing Firdapse Phase III Trial",2013-10-15 11:53:00-04:00,CPRX,positive
291532.0,"Catalyst Pharma Shares Resume, Stock Continues Lower, Now Down to $2.37",2013-10-09 10:27:00-04:00,CPRX,neutral
291533.0,"Shares of Catalyst Pharma Halted on LULD, Price Plunges Nearly 20%",2013-10-09 10:25:00-04:00,CPRX,positive
291534.0,Catalyst Pharma Closes $15.1M Offering,2013-09-10 11:53:00-04:00,CPRX,neutral
291535.0,"Aegis Capital Maintains Buy on Catalyst Pharmaceutical Partners, Inc., Raises PT to $4.00",2013-09-06 09:44:00-04:00,CPRX,neutral
291536.0,Catalyst Pharma Prices 8.8M Shares at $1.72/Share,2013-09-05 09:09:00-04:00,CPRX,positive
291537.0,Morning Market Movers ,2013-08-27 10:16:00-04:00,CPRX,neutral
291538.0,UPDATE: Catalyst Pharma Rises 40% Pre-Market on Breakthrough Therapy Designation for Firdapse for LEMS,2013-08-27 08:13:00-04:00,CPRX,neutral
291539.0,UPDATE: Catalyst Pharma Rises 20% Pre-Market on Breakthrough Therapy Designation for Firdapse for LEMS,2013-08-27 08:10:00-04:00,CPRX,neutral
291540.0,Catalyst Pharma Reports Breakthrough Therapy Designation for Firdapse for LEMS,2013-08-27 08:04:00-04:00,CPRX,neutral
291541.0,UPDATE: Aegis Capital Raises PT on Catalyst Pharmaceutical Following 2Q 2013 Financial Results,2013-08-16 09:10:00-04:00,CPRX,neutral
291542.0,"Aegis Capital Maintains Buy on Catalyst Pharmaceutical Partners, Inc., Raises PT to $3.00",2013-08-16 08:30:00-04:00,CPRX,neutral
291543.0,"Catalyst Pharmaceutical Partners, Inc. Reports Q2 EPS of $(0.06) vs $(0.07) Est",2013-08-15 08:03:00-04:00,CPRX,neutral
291544.0,Catalyst Pharmaceutical Partners Provides Update on FIRDAPSE(TM) Progress ,2013-06-27 08:06:00-04:00,CPRX,positive
291545.0,Catalyst Pharma Partners Win Extension to Regain Compliance with NASDAQ Listing Requirements,2013-06-25 11:36:00-04:00,CPRX,positive
291546.0,"Catalyst Pharmaceutical Partners, Inc. Reports Q1 EPS of $(0.04) vs $(0.08) Est",2013-05-16 08:04:00-04:00,CPRX,neutral
291547.0,Small Cap Biotech Hot Again: How To Play It,2013-04-22 14:03:00-04:00,CPRX,positive
291548.0,"Aegis Capital Initiates Coverage on Catalyst Pharmaceutical Partners, Inc. at Buy, Announces $2.50 PT",2013-04-18 10:03:00-04:00,CPRX,neutral
291549.0,Catalyst Pharma Announces Recommendation of Data Monitoring Committee for Pivotal Phase lll Clinical Trial for Firdapse,2013-03-27 08:04:00-04:00,CPRX,neutral
291550.0,"Catalyst Pharma Names Bernardino Mosquera as VP, Clinical Operations",2013-03-05 08:04:00-05:00,CPRX,neutral
291551.0,Catalyst Pharma Offers Update on R&D Pipeline,2013-02-11 08:10:00-05:00,CPRX,neutral
291552.0,Catalyst Pharma Receives NASDAQ Deficiency Letter,2012-12-27 08:04:00-05:00,CPRX,neutral
291553.0,Catalyst Pharma Partners Announces Automatic Conversion of $5M Promissory Note Into Common Shares,2012-12-11 08:07:00-05:00,CPRX,positive
291554.0,Catyalyst Pharmaceutical Partners Reports Q3 EPS $-0.08 vs $-0.08 Est,2012-11-15 08:09:00-05:00,CPRX,neutral
291555.0,Catalyst Pharma Shares Resume Trading Down 60%,2012-11-08 08:33:00-05:00,CPRX,positive
291556.0,Catalyst Pharma Says CPP-109 Did Not Meet Primary Endpoint,2012-11-08 08:08:00-05:00,CPRX,neutral
291557.0,Shares of Catalyst Pharma to Resume Trading at 8:30AM EST,2012-11-08 08:07:00-05:00,CPRX,positive
291558.0,Catalyst Pharma Trading Halted News Pending,2012-11-08 07:55:00-05:00,CPRX,neutral
291559.0,Morning Market Losers,2012-09-26 09:57:00-04:00,CPRX,negative
291560.0,Catalyst Pharma Says Results on Cocaine Addiction Trial will be Delayed; Sees Top-Line Results in November ,2012-09-26 08:06:00-04:00,CPRX,negative
291561.0,Catalyst Pharma Closes Previously Announced $6 Million Registered Direct Offering,2012-08-30 15:24:00-04:00,CPRX,neutral
291562.0,Catalyst Pharmaceutical Partners Falls 15% Pre-Market on Offering,2012-08-28 08:10:00-04:00,CPRX,neutral
291563.0,Catalyst Pharma Selling 4M at $1.50; to Raise $6M,2012-08-28 08:07:00-04:00,CPRX,neutral
291564.0,UPDATE: Rodman & Renshaw Upgrades Catalyst Pharmaceuticals Partners to Market Outperform  ,2012-08-27 11:51:00-04:00,CPRX,neutral
291565.0,"Rodman & Renshaw Upgrades Catyalyst Pharmaceutical Partners from Market Perform to Market Outperform, Announces PT of $3.70",2012-08-27 11:37:00-04:00,CPRX,neutral
291566.0,Catalyst Pharmaceutical Rises 11% Pre-Market Ahead of Upcoming Phase II Data,2012-08-24 08:56:00-04:00,CPRX,neutral
291567.0,Catyalyst Pharmaceutical Partners Reports Q2 EPS $-0.01 May Not Compare to $-0.05 Est,2012-08-15 08:06:00-04:00,CPRX,neutral
291568.0,Catalyst Pharmaceutical Partners Regains Compliance With NASDAQ Minimum Bid Price Rule ,2012-08-03 09:09:00-04:00,CPRX,neutral
291569.0,"Benzinga's Microcap Movers for Tuesday July 24, 2012",2012-07-24 17:45:00-04:00,CPRX,neutral
291570.0,"Benzinga's Microcap Movers for Thursday July 12, 2012",2012-07-12 16:21:00-04:00,CPRX,neutral
291571.0,Catalyst Pharmaceutical Partners to Announce Top-Line Data From CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction Earlier Than Expected ,2012-07-12 08:03:00-04:00,CPRX,neutral
291572.0,Catalyst Pharmaceutical Partners Prices Underwritten Offering; 6M Units at $0.80/Unit,2012-05-24 08:45:00-04:00,CPRX,neutral
291573.0,Catalyst Pharmaceutical Partners Reports Positive Results From Phase I(a) Clinical Study of CPP-115 ,2012-05-22 08:07:00-04:00,CPRX,positive
291574.0,Catalyst Pharmaceutical Partners Announces Completion of Enrollment in CPP-109 Phase II(b) Clinical Trial for the Treatment of Cocaine Addiction ,2012-05-21 11:00:00-04:00,CPRX,neutral
291575.0,Catalyst Pharmaceutical Partners Offering 10.5M Units ,2012-05-04 09:55:00-04:00,CPRX,neutral
291576.0,Catalyst Pharmaceutical Partners Granted Orphan Medicinal Product Designation in European Union for CPP-115,2012-02-13 09:03:00-05:00,CPRX,positive
291577.0,Catalyst Pharmaceutical Partners Files U.S. Provisional Patent Application for GABA Aminotransferase Inhibitor Use in Treatment of Tourette Syndrome  ,2012-02-09 08:03:00-05:00,CPRX,negative
291578.0,Catalyst Pharmaceutical Partners Announces FDA Designation of CPP-115 as a Fast Track Development Program  ,2011-12-20 10:14:00-05:00,CPRX,neutral
291579.0,Trading Halted in Catalyst Pharmaceuticals,2011-12-20 09:58:00-05:00,CPRX,neutral
291580.0,Scientific Paper Regarding CPP-115 for the Treatment of Cocaine Addiction Accepted for Publication in the Journal of Medicinal Chemistry ,2011-12-15 08:07:00-05:00,CPRX,positive
291581.0,Catalyst Pharmaceutical Jumps on High Volume,2011-11-18 14:35:00-05:00,CPRX,neutral
291582.0,Catalyst Pharmaceutical Partners Announces Public Offering of 3.04M Common Shares and 1.52M Warrants ,2011-10-28 09:28:00-04:00,CPRX,positive
291583.0,"Biotech/Pharma Stocks to Watch: BioSante, RXi, Dendreon, Catalyst Pharmaceutical Partners",2011-09-13 12:10:00-04:00,CPRX,neutral
291584.0,Rodman & Renshaw Maintains Market Perform on Catalyst Pharmaceutical Partners,2011-06-17 06:00:00-04:00,CPRX,neutral
291585.0,Catalyst Pharmaceutical Partners Reports Positive Non-Clinical Efficacy Results Evaluating CPP-115 for the Treatment of Infantile Spasms,2011-06-16 15:03:00-04:00,CPRX,positive
291586.0,Morning Market Losers ,2011-06-06 09:56:00-04:00,CPRX,negative
291587.0,Catalyst Announces Commencement of CPP-109 Investigator-Sponsored Study in Cocaine and Alcohol Co-Dependent Patients  ,2011-03-29 08:11:00-04:00,CPRX,neutral
291588.0,"Catalyst Pharmaceutical Partners, Inc. Announces Public Offering of 2.26M Shares at $1.12 per Share",2011-03-08 09:10:00-05:00,CPRX,positive
291589.0,Orphan Status for Catalyst Drug - Analyst Blog,2010-09-22 20:12:00-04:00,CPRX,neutral
291590.0,"Stocks to Watch (ASTI,LWSN,UAUA,CRPX,BCRX)",2009-10-01 06:37:00-04:00,CPRX,neutral
